Loading
HKSEHealthcareMedical - Care Facilities
Latest quote
HK$10.36
−HK$0.29 · -2.72%
Hygeia Healthcare Holdings Co., Limited (6078.HK) is a prominent oncology healthcare provider primarily operating across the People's Republic of China. The company owns and manages a network of private, for-profit hospitals specializing in comprehensive cancer care. These facilities offer a broad spectrum of services, including diagnostic procedures such as tumor screening and genetic analysis, advanced therapeutic interventions like radiotherapy, surgery, chemotherapy, immunotherapy, and targeted treatments, alongside crucial supportive care including oncology rehabilitation, nutritional guidance, and hospice services. Beyond direct patient care, Hygeia also provides consulting expertise for radiotherapy centers and licenses its specialized SRT (Stereotactic Radiotherapy) equipment, offering ongoing maintenance and technical support for these systems. The company's operations extend to providing hospital and corporate management services, as well as supply chain solutions. By the end of 2021, Hygeia Healthcare had established a significant presence, operating or managing 12 oncology-focused hospitals spread across 9 cities in 7 provinces throughout mainland China. Established in 2009, the company maintains its headquarters in Shanghai, PRC.
Latest quote
HK$10.36
−HK$0.29 · -2.72%
Regular session · HKT · Market data may be delayed.
Hygeia Healthcare Holdings Co., Limited (6078.HK) is a prominent oncology healthcare provider primarily operating across the People's Republic of China. The company owns and manages a network of private, for-profit hospitals specializing in comprehensive cancer care. These facilities offer a broad spectrum of services, including diagnostic procedures such as tumor screening and genetic analysis, advanced therapeutic interventions like radiotherapy, surgery, chemotherapy, immunotherapy, and targeted treatments, alongside crucial supportive care including oncology rehabilitation, nutritional guidance, and hospice services. Beyond direct patient care, Hygeia also provides consulting expertise for radiotherapy centers and licenses its specialized SRT (Stereotactic Radiotherapy) equipment, offering ongoing maintenance and technical support for these systems. The company's operations extend to providing hospital and corporate management services, as well as supply chain solutions. By the end of 2021, Hygeia Healthcare had established a significant presence, operating or managing 12 oncology-focused hospitals spread across 9 cities in 7 provinces throughout mainland China. Established in 2009, the company maintains its headquarters in Shanghai, PRC.
Day range
Current HK$10.36
52-week range
Current HK$10.36
Regular session · HKT · Market data may be delayed.
Hygeia Healthcare Holdings Co., Limited (6078.HK) is a prominent oncology healthcare provider primarily operating across the People's Republic of China. The company owns and manages a network of private, for-profit hospitals specializing in comprehensive cancer care. These facilities offer a broad spectrum of services, including diagnostic procedures such as tumor screening and genetic analysis, advanced therapeutic interventions like radiotherapy, surgery, chemotherapy, immunotherapy, and targeted treatments, alongside crucial supportive care including oncology rehabilitation, nutritional guidance, and hospice services. Beyond direct patient care, Hygeia also provides consulting expertise for radiotherapy centers and licenses its specialized SRT (Stereotactic Radiotherapy) equipment, offering ongoing maintenance and technical support for these systems. The company's operations extend to providing hospital and corporate management services, as well as supply chain solutions. By the end of 2021, Hygeia Healthcare had established a significant presence, operating or managing 12 oncology-focused hospitals spread across 9 cities in 7 provinces throughout mainland China. Established in 2009, the company maintains its headquarters in Shanghai, PRC.
Day range
Current HK$10.36
52-week range
Current HK$10.36
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (CNY) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 4.01B CNY | 4.45B CNY | 4.08B CNY | 3.2B CNY | 2.32B CNY |
| Cost of goods sold | 2.99B CNY | 3.12B CNY | 2.81B CNY | 2.18B CNY | 1.57B CNY |
| Gross profit | 1.02B CNY | 1.33B CNY | 1.27B CNY | 1.02B CNY | 744.66M CNY |
| Research and development | 10.05M CNY | 13.24M CNY | — | — | — |
| Selling, general, and administrative | 469.56M CNY | 490.73M CNY | 413.34M CNY | 292.95M CNY | 225.42M CNY |
| Operating expenses | 630.05M CNY | 508.33M CNY | 377.77M CNY | 350.25M CNY | 150.88M CNY |
| Interest income | 3.26M CNY | 1.51M CNY | 10.15M CNY | 17.32M CNY | 2.16M CNY |
| Interest expense | 69.15M CNY | 71.84M CNY | 43.17M CNY | 34.88M CNY | 23.09M CNY |
| Depreciation and amortization | 267.68M CNY | 260.36M CNY | 180.56M CNY | 132.66M CNY | 98.06M CNY |
| Operating income | 393.43M CNY | 821.14M CNY | 889.1M CNY | 666.82M CNY | 593.78M CNY |
| Net income | 164.53M CNY | 598.26M CNY | 682.93M CNY | 476.78M CNY | 441.46M CNY |
Company facts updated Sep 7, 2026.
Recent quarterly results
Recent quarterly results
Cash distributions grouped by calendar year; partial years are marked.
HK$0.1636
2023 complete year+13.6% since 2021
HK$0.1441
2,021
HK$0.1636
2,023
| Action | Ex-dividend date | Details | Record date | Payment date |
|---|---|---|---|---|
Dividend | Jun 30, 2023 | HK$0.1636Irregular | Jul 3, 2023 | Jul 27, 2023 |
Dividend | Jun 30, 2021 | HK$0.1441Irregular | Jul 5, 2021 | Jul 26, 2021 |
Ex-dividend Jun 30, 2023
HK$0.1636
Irregular
Record Jul 3, 2023 · Payment Jul 27, 2023
Ex-dividend Jun 30, 2021
HK$0.1441
Irregular
Record Jul 5, 2021 · Payment Jul 26, 2021
Funds reporting this stock among their holdings, ordered by reported position size.
iShares Core MSCI Emerging Markets ETFIEMG6.5M0.00%163.85B USD0.09%$83.65+1.65%
Vanguard Total International Stock ETFVXUS6.23M0.00%646.2B USD0.05%$88.41+0.50%
Vanguard FTSE Emerging Markets ETFVWO5.75M0.00%162.3B USD0.06%$61.44+0.74%
Vanguard FTSE All-World ex-US Small-Cap ETFVSS1.96M0.01%13.6B USD0.06%$161.34+0.42%
iShares Core MSCI Total International Stock ETFIXUS1.49M0.00%61.15B USD0.07%$98.71+0.57%
Dimensional - Emerging Markets Core Equity 2 ETFDFEM938.81K0.01%9.54B USD0.39%$41.00+1.36%
State Street SPDR Portfolio Emerging Markets ETFSPEM675.65K0.00%17.77B USD0.07%$53.41+0.77%
Avantis Emerging Markets Equity ETFAVEM529.24K—28.22B USD0.33%$96.81+1.52%iShares Core MSCI Emerging Markets ETFIEMGVanguard Total International Stock ETFVXUSVanguard FTSE Emerging Markets ETFVWOVanguard FTSE All-World ex-US Small-Cap ETFVSSiShares Core MSCI Total International Stock ETFIXUSDimensional - Emerging Markets Core Equity 2 ETFDFEMState Street SPDR Portfolio Emerging Markets ETFSPEMAvantis Emerging Markets Equity ETFAVEMAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
